Start with a deadline.
A new Section 232 tariff regime, with rates as high as 100% on patented drugs, begins phasing in July 31, 2026, turning what had been a longer-term strategic push into a hard compliance deadline. That’s not a distant policy threat. That’s this month.
Now think about what happens next. Not to Pfizer or Lilly. Not to the CDMOs scrambling to build capacity. Think two levels deeper — to the companies that supply the equipment inside every one of those new factories.
Because here’s the thing most investors are missing: announced reshoring commitments exceed $480 billion across 22 sites and roughly 44,000 jobs, yet upstream equipment suppliers have not seen order flow commensurate with even modest capex conversion assumptions. That gap between announced intent and actual equipment orders is the trade. And it’s closing fast.
Why This Is Happening Right Now
The pharmaceutical supply chain didn’t break overnight. In the early 2000s, only 15% of factories supplying the United States market were located overseas, but by 2020, that number had grown by more than 80%. Decades of offshoring, chasing cheaper labor and looser regulation, created a structure so concentrated that when things go wrong, they go wrong everywhere at once.
And they have been going wrong. According to the American Society of Health-System Pharmacists, there are consistently over 200 active drug shortages in the U.S., many involving essential medications used in hospitals and specialty care. The average drug shortage now lasts longer than any year on record, more than doubling from 2019.
Slight tangent — but it matters. Nearly half, 48%, of drugs included on USP’s vulnerability list have at least one of their key starting materials solely manufactured in one country, which the organization deemed a potential point of failure. You can build a new U.S. factory. You cannot solve a single-country input dependency with a groundbreaking ceremony. That’s the structural problem underneath the political story.
Still, the political story is what’s driving the capital. By late 2025, industry sources estimated that drugmakers had pledged hundreds of billions of dollars to U.S. manufacturing — Lilly announced a $27 billion plan, Merck $70 billion, J&J $55 billion. These are not press release numbers. They are compliance-driven investment decisions with hard deadlines attached.
Who Gets Paid When Every Factory Gets Built
If pharmaceutical companies are steadfast about their new capital investments, their announcements should create a trickle-up effect whereby tangible expansion occurs in the procurement of upstream equipment. To build new biopharma plants and produce biopharmaceuticals, the companies need consumables, reactors, bioprocessors, pipes, mixers, and other specialized infrastructure essential to drug manufacturing.
Even a conservative estimate that 15% of this capital expenditure will go toward purchasing such bioprocessing equipment would amount to more than $75 billion — an unprecedented upswing in revenue for manufacturers of this equipment.
That’s not a rounding error. That’s a category-defining demand surge. And it lands on a relatively small number of specialized suppliers who make the actual tools inside these plants.
Here’s where it gets interesting. The BIOSECURE Act — signed into law December 2025, it has already triggered a massive reshuffling of global CDMO relationships, accelerated reshoring investments, and created both winners and losers across the pharmaceutical supply chain. Companies like Cabaletta Bio warned that losing their supplier could disrupt clinical timelines. Dozens of biotech companies that outsourced manufacturing to WuXi are now scrambling to find alternative capacity in the U.S., Europe, South Korea, or India.
New plants need new equipment. Every single one of them.
The Company Three Layers Deep
The first derivative of pharma reshoring is the CDMOs building capacity. The second derivative is the companies financing those builds. The third derivative — the one Wall Street hasn’t fully priced — is the company selling the critical filtration and purification tools that go inside every biologic manufacturing line, regardless of who builds it or where.
That company is Repligen (RGEN).
Repligen’s core markets include biopharmaceutical manufacturing, biologics, vaccines, and cell and gene therapies. The company does not develop or sell finished drugs itself; instead it supplies equipment, consumables, and process-optimization tools that pharmaceutical manufacturers use. Think of it as the picks-and-shovels company inside every biopharma gold rush — except the gold rush just got a government mandate attached to it.
Repligen’s business centers on supplying technologies used in biologic drug manufacturing, including chromatography columns, filtration systems, and process analytics. Over the long run, Repligen’s addressable market is tied to global spending on biologic medicines, where industry reports point to high-single-digit annual growth. The company’s portfolio positions it as a picks-and-shovels supplier to this trend, with revenue leverage primarily on installed-base expansion, higher utilization of its systems, and the recurring nature of single-use consumables.
That last part matters more than most investors realize. Single-use consumables are not one-time purchases. Every production run burns through them. Once a CDMO installs Repligen’s platform, they keep buying from Repligen. CDMOs operate multiple production lines for different sponsors and can act as multipliers for technology adoption. Once a platform is established at a CDMO, it may be used for numerous programs, benefiting suppliers like Repligen.
What the Numbers Actually Show
In its May 5 earnings release, Repligen posted first-quarter 2026 revenue of $194 million, up 15% year over year, with 11% organic growth. GAAP EPS rose 50% year over year and adjusted EPS rose 23%, while full-year adjusted EPS guidance was increased.
UBS believes that Repligen is uniquely positioned to lead a sustained recovery in the bioprocessing sector, supported by its diversified growth drivers and the accelerating reshoring trend. With over 20% order growth and an expanding footprint in Edge manufacturing, UBS sees Repligen as a core beneficiary as biopharma companies move production closer to their primary markets in 2026.
The part people skip: Repligen CEO Olivier Loeillot was direct, saying that even a fraction of the total reshoring announcements — $50 to $100 billion — would still offer high-growth potential for the equipment industry, with time horizons for breaking ground at 2026 and 2027 at the earliest. Groundbreaking season, in other words, is right now.
For the next three years, revenue is forecast to grow 13% per annum, while earnings are forecast to grow 30% per annum over the same period.
Why Nobody Is Talking About This
Three reasons. First, the headline story is about drug prices and tariffs — that framing sends everyone toward the branded drug companies, not the people selling them bioreactors. Second, Repligen went through a rough 2024 when biotech funding dried up and CDMOs destocked. The hangover from that period still colors how analysts frame the stock. Third, this is a company with a $4-5 billion market cap in an industry where Pfizer and Lilly dominate the conversation.
What the market is getting wrong: the destocking cycle is over, the order recovery is already confirmed in Q1 2026 results, and the $480 billion reshoring wave is just now starting to convert announcements into equipment purchase orders. If pharmaceutical companies are steadfast about their new capital investments, their announcements should create a trickle-up effect whereby tangible expansion occurs in the procurement of upstream equipment. To build new biopharma plants, the companies need consumables, reactors, bioprocessors, pipes, mixers, and other specialized infrastructure.
Repligen sells most of that. And the orders are starting to come.
What to Watch
The next earnings report will be the clearest signal. Order growth commentary from management will matter more than the revenue number itself — what are CDMOs telling Repligen about their build-out timelines? Are equipment conversations converting to signed purchase orders?
Also watch the regulatory calendar. Deadlines tighten quickly, with Annex III firms effective July 31, 2026 and others by September 29, 2026. Each deadline that passes without a policy retreat is another forcing function pushing pharma companies to actually start building — and actually start ordering equipment.
The deeper risk worth monitoring: building a new CDMO facility takes 3–5 years from groundbreaking to FDA approval. Transferring a manufacturing process from one site to another takes 12–24 months of tech transfer, validation, and regulatory submission. That timeline mismatch — fast deadlines, slow build cycles — could create an intermediate period where companies sign letters of intent without yet ordering equipment at scale. That is the gap between announcement and revenue.
The bull case doesn’t need all $480 billion to materialize. It just needs a fraction of it to start moving.
For informational purposes only.
